Smith J, Ezekwe N, Pourang A, and Hamzavi I. Multifocal Myositis and Elevated CPK associated with the use of Ustekinumab for Hidradenitis Suppurativa. Br J Dermatol 2020.
The British journal of dermatology
ustekinumab (UST) is a human interleukin (IL)-12/IL-23 monoclonal antibody that has been approved by the Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Off-label use of UST has shown promising results for hidradenitis suppurativa (HS) in patients that have failed therapy with adalimumab, the only FDA approved treatment for HS.
ePub ahead of print
Available for download on Wednesday, December 29, 2021